Table 2 Characteristics of patients
Characteristics | No. | % |
|---|---|---|
Eligible patients | 35 | |
Patients assessable | ||
for toxicity | 35 | 100 |
for response | 35 | 100 |
Men/women | 27/8 | 77/23 |
Age (years) median (range) | 62 (25–75) | |
Performance status (Karnofsky) | ||
100% | 7 | 20 |
90% | 14 | 40 |
80% | 12 | 34.3 |
70% | 2 | 5.7 |
Time from diagnosis to first metastases | ||
<12 months | 25 | 71.4 |
⩾12 months | 10 | 28.6 |
Prior nephrectomy | 35 | 100 |
Prior immunotherapy | ||
IFN | 21 | 60 |
IL-2 | 9 | 25.7 |
IL-2+IFN | 5 | 14.3 |
Response to first-line immunotherapy | ||
IFN (CR, PR, SD, PD) | 1, 2, 12, 6 | |
IL-2 (CR, PR, SD, PD) | 0, 1, 4, 4 | |
IL-2+IFN (CR, PR, SD, PD) | 0, 2, 2, 1 | |
Site of metastatic disease | ||
Lung | 27 | 77.1 |
Mediastinal lymph nodes | 14 | 40 |
Bone | 6 | 17 |
Abdominal lymph nodes | 5 | 14 |
Liver | 4 | 11 |
Recurrence at nephrectomy site | 3 | 9 |
Others | 8 | 23 |
Number of sites with metastases | ||
1 | 9 | 25.7 |
>1 | 26 | 74.3 |
